[en] Background: Fatigue is common among patients with inflammatory bowel diseases (IBDs) and is associated with decreased quality of life (QoL). Aims: Describe fatigue evolution and identify factors associated with fatigue outcomes in patients with ulcerative colitis (UC) or Crohn's disease (CD) initiating biologic treatment. Methods: Data from adult Belgian patients with UC or CD enrolled in a prospective real-world study were utilized. Fatigue and QoL were assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and the Short Inflammatory Bowel Disease Questionnaire, respectively. Factors associated with fatigue outcomes were assessed using multivariate regression. Results: 465 patients were included: 174 with UC and 291 with CD. Average FACIT-F scores indicated improvements in fatigue after 6 months, before stabilizing. A higher probability of fatigue disappearance was associated with clinical remission and was more likely in patients with UC than CD. Patients achieving clinical remission had lower probability of fatigue. Patients with fatigue improvements experienced greater QoL improvements than patients with fatigue persistence. Conclusions: Real-world findings suggest fatigue partly improves in the first 6 months of biologic treatment. Clinical remission was associated with greater probability of fatigue disappearance and lower likelihood of fatigue persistence. Further research into factors associated with fatigue in patients with IBD is warranted.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Bossuyt, Peter; Imelda GI Clinical Research Center, Imelda General Hospital, Bonheiden, Belgium
Colard, Arnaud ; Université de Liège - ULiège > Département des sciences cliniques ; Department of Gastroenterology, Hospital CHC, Liège, Belgium
Nakad, Antoine; Department of Gastroenterology, CHwapi Notre Dame, Tournai, Belgium
Baert, Didier; Department of Gastroenterology, Maria Middelares Medical Centre, Ghent, Belgium
Mana, Fazia; Department of Gastroenterology, Clinique St. Jean, Brussels, Belgium
Caenepeel, Philip; Department of Gastroenterology, Ziekenhuis Oost Limburg, Genk, Belgium
Branden, Stijn Vanden; Department of Gastroenterology, Onze Lieve Vrouwziekenhuis, Aalst, Belgium
Vermeire, Severine; Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium
D'Heygere, Francois; Department of Gastroenterology, AZ Groeninge Hospital, Kortrijk, Belgium
Strubbe, Beatrijs; Department of Gastroenterology, AZ St Lucas, Ghent, Belgium
Cremer, Anneline; Department of Gastroenterology, Hopital Universitaire Erasme, Brussels, Belgium
Setakhr, Vida; Department of Gastroenterology, CHU UCL Namur site Sainte Elisabeth, Namur, Belgium
Baert, Filip; Department of Gastroenterology, AZ Delta, Roeselare, Belgium
Vijverman, Anne ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie ; Department of Gastroenterology, Hospital CHR de la Citadelle, Liège, Belgium
Coenegrachts, Jean-Louis; Department of Gastroenterology, Jessa Ziekenhuis, Hasselt, Belgium
Flamme, Frederic; Department of Gastroenterology, CHU Ambroise Paré, Mons, Belgium
Ungaro, R., Mehandru, S., Allen, P.B., et al. Ulcerative colitis. Lancet 389:10080 (2017), 1756–1770.
GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 5:1 (2020), 17–30.
Ng, S.C., Shi, H.Y., Hamidi, N., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390:10114 (2017), 2769–2778.
Radford, S.J., McGing, J., Czuber-Dochan, W., et al. Systematic review: the impact of inflammatory bowel disease-related fatigue on health-related quality of life. Frontline Gastroenterol 12:1 (2021), 11–21.
Schreiner, P., Rossel, J.B., Biedermann, L., et al. Fatigue in inflammatory bowel disease and its impact on daily activities. Aliment Pharmacol Ther 53:1 (2021), 138–149.
Dibley, L., Bager, P., Czuber-Dochan, W., et al. Identification of research priorities for inflammatory bowel disease nursing in Europe: a nurses-European Crohn's and Colitis Organisation Delphi survey. J Crohns Colitis 11:3 (2017), 353–359.
Ben-Horin, S., Novack, L., Mao, R., et al. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: a systematic review and an individual-patient data meta-analysis of randomized controlled trials. Gastroenterology 162:2 (2022), 482–494.
Cholapranee, A., Hazlewood, G.S., Kaplan, G.G., et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther 45:10 (2017), 1291–1302.
Katsanos, K.H., Papamichael, K., Feuerstein, J.D., et al. Biological therapies in inflammatory bowel disease: beyond anti-TNF therapies. Clin Immunol 206 (2019), 9–14.
Lasa, J.S., Olivera, P.A., Danese, S., et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 7:2 (2022), 161–170.
Feuerstein, J.D., Ho, E.Y., Shmidt, E., et al. AGA Clinical Practice Guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology 160:7 (2021), 2496–2508.
Lichtenstein, G.R., Loftus, E.V., Isaacs, K.L., et al. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol 113:4 (2018), 481–517.
Raine, T., Bonovas, S., Burisch, J., et al. ECCO Guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis 16:1 (2022), 2–17.
Rubin, D.T., Ananthakrishnan, A.N., Siegel, C.A., et al. ACG Clinical Guideline: ulcerative colitis in adults. Am J Gastroenterol 114:3 (2019), 384–413.
Torres, J., Bonovas, S., Doherty, G., et al. ECCO Guidelines on therapeutics in Crohn's disease: medical treatment. J Crohns Colitis 14:1 (2020), 4–22.
Tinsley, A., Macklin, E.A., Korzenik, J.R., et al. Validation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) in patients with inflammatory bowel disease. Aliment Pharmacol Ther 34:11–12 (2011), 1328–1336.
Christensen, K.R., Ainsworth, M.A., Steenholdt, C., et al. Fatigue is a systemic extraintestinal disease manifestation largely independent of disease activity, chronicity, and nutritional deficiencies in inflammatory bowel disease on biologics. Scand J Gastroenterol 57:9 (2022), 1051–1057.
Villoria, A., García, V., Dosal, A., et al. Fatigue in out-patients with inflammatory bowel disease: prevalence and predictive factors. PLoS One, 12(7), 2017, e0181435.
Cella, D., Sarda, S.P., Hsieh, R., et al. Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study. Ann Hematol 101:9 (2022), 1905–1914.
Regueiro, M., Delbecque, L., Hunter, T., et al. Experience and measurement of fatigue in adults with Crohn's disease: results from qualitative interviews and a longitudinal 2-week daily diary pilot study. J Patient Rep Outcomes, 7(1), 2023, 75.
Montan, I., Löwe, B., Cella, D., et al. General population norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue scale. Value Health 21:11 (2018), 1313–1321.
Irvine, E.J., Zhou, Q., Thompson, A.K., The short inflammatory bowel disease questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's relapse prevention trial. Am J Gastroenterol 91:8 (1996), 1571–1578.
Bager, P., Befrits, R., Wikman, O., et al. Fatigue in out-patients with inflammatory bowel disease is common and multifactorial. Aliment Pharmacol Ther 35:1 (2012), 133–141.
Graff, L.A., Clara, I., Walker, J.R., et al. Changes in fatigue over 2 years are associated with activity of inflammatory bowel disease and psychological factors. Clin Gastroenterol Hepatol 11:9 (2013), 1140–1146.
Klusmann, B., Fleer, J., Tovote, K.A., et al. Trajectories of fatigue in inflammatory bowel disease. Inflamm Bowel Dis 27:12 (2021), 1919–1930.
van Langenberg, D.R., Gibson, P.R., Systematic review: fatigue in inflammatory bowel disease. Aliment Pharmacol Ther 32:2 (2010), 131–143.
McNelly, A.S., Nathan, I., Monti, M., et al. The effect of increasing physical activity and/or omega-3 supplementation on fatigue in inflammatory bowel disease. Gastrointest Nurs 14:8 (2016), 39–50.
van Langenberg, D.R., Gibson, P.R., Factors associated with physical and cognitive fatigue in patients with Crohn's disease: a cross-sectional and longitudinal study. Inflamm Bowel Dis 20:1 (2014), 115–125.
Truyens, M., De Ruyck, E., Gonzales, G.B., et al. Prevalence of fatigue and unrecognized depression in patients with inflammatory bowel disease in remission under immunosuppressants and biologicals. J Clin Med, 10(18), 2021, 4108.
